|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Angiotensin II sustains brain inflammation in mice via TGF-[Beta]显示文摘 | Lanz Tobias V Ding Zhaoqing Ho Peggy P Luo Jian Agrawal Ankur N Srinagesh Hrishikesh Axtell Robert Zhang Hui Platten Michael Wyss-Coray Tony Steinman Lawrence | 2010 | Journal of Clinical Investigation2010，，8： | 1 |
| 2 | Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmac- ophores显示文摘 | Bin Ho A Michael Cridera James P Stablesb | 2001 | European Journal of Medicinal Chemistry2001，36，3： | 1 |
| 3 | Synthesis and structure-activity relationships of potential anticonvulsants based on 2 -piperidinecarboxylic acid and related pharmacophores显示文摘 | Bin Ho A Michael Cridera James P Stablesb | 2001 | European Journal of Medicinal Chemistry2001，36，3： | 1 |
| 4 | Synthesis and structure-activity relationships of potential anticonvulsants based on 2-pip-eridinecarboxylic acid and related pharmacophores显示文摘 | Ho B Michael C A Stables J P | 2001 | Eur J Med Chem2001，36，3： | 1 |
| 5 | Risk of ad- verse outcome associated with concomitant use of clopi- dogrel and proton pump inhibiters following acute coronary syndrome显示文摘 | P Michael Ho Tomas M Maddox | 2009 | J Am Med Assoc2009，301，9： | 1 |
| 6 | Evaluating the Evidence: Is There a Rigid Hierarchy?显示文摘 | P Michael Ho Pamela N. Peterson Frederick A. Masoudi | 2008 | Circulation2008，，16： | 1 |
| 7 | Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome显示文摘 | MICHAEL HO P MADDOX TM FIHN SD | 2009 | J Ame Med Assoc2009，301，9： | 1 |
| 8 | Depression and Cardiovascular Disease: A Call For Recognition显示文摘 | John S. Rumsfeld P Michael Ho | 2005 | Circulation2005，，3： | 1 |
| 9 | Confirmation of the beneficial effects of brief co-incubation of gametesin human in vitro fertilization显示文摘 | Quinn P Michael LL Minh Ho | 1998 | Fertil Steril1998，69，： | 1 |
| 10 | Activation of invariant NKT cells en- hances the innate immune response and improves the disease course in influenza A virus infection显示文摘 | Ho L P Denney L Luhn K Teoh D Clelland C Mc- Michael AJ | 2008 | Eur J Immunol2008，38，7： | 1 |
| 11 | HM30181A,a potent P-glycoprotein inhibitor,potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model显示文摘Objective:Delivery of chemotherapeutic drugs to the brain has remained a major obstacle in the treatment of glioma,owing to the presence of the blood-brain barrier and the activity of P-gp,which pumps its substrate back into the systemic circulation.The aim of the present study was to develop an intravenous formulation of HM30181 A(HM)to inhibit P-gp in the brain to effectively deliver paclitaxel(PTX)for the treatment of malignant glioma.Methods:Two formulations of solubilized HM were designed on the basis of different solid dispersion strategies:i)spray-drying[polyvinlypyrrolidone(PVP)-HM]and ii)solvent evaporation[HP-β-cyclodextrin(cyclodextrin)-HM].The P-gp inhibition of these 2 formulations was assessed on the basis of rhodamine 123 uptake in cancer cells.Blood and brain pharmacokinetic parameters were also determined,and the antitumor effect of cyclodextrin-HM with PTX was evaluated in an orthotopic glioma xenograft mouse model.Results:Although both PVP-HM and cyclodextrin-HM formulations showed promising P-gp inhibition activity in vitro,cyclodextrin-HM had a higher maximum tolerated dose in mice than did PVP-HM.Pharmacokinetic study of cyclodextrin-HM revealed a plasma concentration plateau at 20 mg/kg,and the mice began to lose weight at doses above this level.Cyclodextrin-HM(10 mg/kg)administered with PTX at 10 mg/kg showed optimal antitumor activity in a mouse model,according to both tumor volume measurement and survival time(P<0.05).Conclusions:In a mouse orthotopic brain tumor model,the intravenous co-administration of cyclodextrin-HM with PTX showed potent antitumor effects and therefore may have potential for glioma therapy in humans. | Wu Zeng Betty Yuen Kwan Law Vincent Kam Wai Wong Denise So Bik Chan Simon Wing Fai Mok Joyce Jia Ying Gao Rebecca Ka Yan Ho Xu Liang Jia Hao Li Ming Tsung Lee Weng Li Yoon Michael P Smolinski Johnson Yiu Nam Lau Christopher Wai Kei Lam Manson Fok | 2020 | Cancer Biology & Medicine2020，17，4： | 0 |
| 12 | 心血管病患者的用药依从性显示文摘心血管疾病是全球主要死亡的原因。虽然药理学的进步降低了心血管疾病相关的发病率和死亡率,但不遵从处方治疗仍然是改善患者整体预后的一个重大障碍。多种提高用药依从性的策略已经在临床试验中得到了验证,包括以下几类:加强患者教育、实行用药提醒、认知行为干预、降低用药成本、医疗团队成员参与以及简化给药方案。在这篇综述中,我们对每个类别的具体试验进行了阐述和分析,着重强调每种干预措施对患者用药依从性的影响。我们还调查了正在进行的,旨在改善心血管疾病患者用药依从性的试验,并且对未来的研究方向进行了预测。 | Steven T Simon Vinay Kini Andrew E Levy P Michael Ho 邓晓春(译) 莫云凌(校) | 2022 | 英国医学杂志中文版2022，25，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员